Moderna bounces back with spotlight on other vaccine stocks (MRNA, DYAI, NVAX, JNJ, AZN, BNTX, PFE)

Stock of Moderna (MRNA) is currently trading at $396.33 USD up 2.85% today. The week has been full on volatility with stock prices gaining 17% on Monday, lagging 5.7% on Tuesday, and fell again on Wednesday. The entire year 2021 has been a dream year for MRNA. Moderna  surged by over 300% over that period, beating the S&P 500, which climbed 18.%; the iShares Biotechnology ETF (IBB), which was up 14%; and the SPDR S&P Biotech ETF (XBI), which fell 11%. Moderna announced its quarterly earnings on Thursday that had a spiral effect on the stock prices. Oppenheimer analyst Hartaj Singh and Piper Sandler analyst Edward Tenthoff downgraded the stock on their ratings. Singh dropped his rating to Perform from Outperform, while Tenthoff cut it to neutral from overweight. Will this affect the pps of other vaccine stocks such as MRNA, DYAI, NVAX, JNJ, AZN, BNTX, PFE ?

To get a complete stock analysis report on MRNA and other vaccine stock visit:

Please make sure to read and completely understand our disclaimer at While reading this article one must assume that we may be compensated for posting this content on our website.